Jim LaFlamme just made a multimillion-dollar bequest to the UConn School of Pharmacy, a gift that anyone who knew him back in the \u201970s would never have predicted.<\/p>\n
This is, after all, the same Jim LaFlamme \u201979 (PHAR) who had a reputation as a bit of a troublemaker with little regard for classroom learning back then. \u201cI mean, I took full advantage of the 18-year-old drinking age when I was at UConn,\u201d LaFlamme says. \u201cI didn\u2019t take anything seriously because I had a photographic memory. For the first two years, I didn\u2019t go to class at all. I took the tests, and that was it.\u201d<\/p>\n
LaFlamme readily admits that without the counsel of the dean at the time, Karl Nieforth, he wouldn\u2019t have graduated.\u201cHe told me, \u2018You may not see it yourself, but you\u2019re destined for something great. You don\u2019t have confidence in yourself, but I have confidence in you.\u2019 I said to myself, \u2018Shoot, now I owe this guy something, and I can\u2019t let him down.\u2019\u201d<\/p>\n
Something Great<\/strong><\/p>\n The dean was right. LaFlamme earned a master\u2019s degree in management from Indiana Wesleyan University and went on to a distinguished and diverse health care career. He served as executive vice president with Cot\u00e9 Orphan, responsible for all global operations within both the regulatory affairs and business development divisions and was a director with Pricewaterhouse Coopers, advising healthcare clients in both the public and commercial sectors. Early in his career, LaFlamme held director of pharmacy, administrative, and executive positions with medical centers in Maine, Indiana, Connecticut, and Colorado.<\/p>\n Four years ago, he started his own company, BioPharma Global in Vienna, Virginia, which shepherds pharmaceuticals used to treat rare \u201corphan diseases\u201d through the FDA\u2019s regulatory process. An orphan disease affects fewer than 200,000 people. LaFlamme was inspired in part because he hopes to find a treatment for his own inflammatory condition, which has yet to be named.<\/p>\n